NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
... particle (VLP) vaccine candidate against the H1N1 pandemic
influenza virus under current good-manufacturing ... has plans to produce additional batches of the pandemic
H1N1 VLP vaccine to support human clinical ... influenza vaccine within 12 weeks under real pandemic
conditions is an important and successful test of ...
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
... (VE) Patch in combination with an injectable H5N1 pandemic
influenza vaccine started today in the U.S.
... the dosage and improve protection against an H5N1 pandemic
influenza outbreak with only a single dose ... its VE Patch to improve prevention of H5N1 pandemic
influenza with the start of a Phase II clinical ...
EPSScentral Responds to Pandemic Alert
... the WHO, phase 5 ... is a strong signal that a pandemic
is imminent and that the time to ... ... and performance, EPSScentral, together with pandemic
content experts and technology partners, developed a package to address pandemic
planning needs. Commencing with the SARS and ...
USAID Cooperates in Pandemic Preparedness Initiative
... off the implementation stage of its Humanitarian pandemic
Preparedness initiative. The three-day exercise ... emerging infectious disease will spark a global pandemic
remains a significant threat. In a pandemic, ... need access to food, water, and care for both pandemic
and non-pandemic illnesses. Through the ...
USAID Provides $5M in Emergency Support as Swine Flu Spreads
... 2005, USAID has committed $543 million to support pandemic
prevention and preparedness across the globe," ... On April 27, WHO raised the level of influenza pandemic
alert to Phase 4, indicating an increased ... alert level does not necessarily mean that a pandemic
is inevitable. WHO sent a team of responders, ...
Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
... doses to, perhaps, several billion doses in a pandemic
situation, company officials said.
... may provide some protection even against a pandemic
caused by a different strain of H5N1. She also ... it may make sense to vaccinate people prior to a pandemic
with the licensed vaccine and then, if ...
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
... - Has Potential to Address Gaps in Global pandemic
ROCKVILLE, Md., Feb. 17 ... Health Organization Meeting on Evaluation of pandemic
Influenza Prototype Vaccines in Clinical Trials, ... of the Phase I/IIa human clinical trial of its pandemic
influenza virus-like particle (VLP) vaccine ...
USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
... additional funding of
USD 12.5 m for Intercell's pandemic
Intercell is developing a pandemic
Influenza Vaccine Patch System that
includes an ... immune response and enable
dose sparing of the pandemic
The actual funding ...
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
... vaccine program follows positive results from its pandemic
influenza vaccine Phase IIa trial in July 2008; ... influenza results in combination with the pandemic
influenza results released in August of this ... current results may not be predictive of future pandemic
results, results of our seasonal influenza ...
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
... the company's Vaxfectin (R)-formulated H5N1 pandemic
influenza DNA vaccines induced T-cell responses ... (Las Vegas - December 9-11).
Influenza Vaccine Phase 1 Trial Update
New ... company's monovalent Vaxfectin(R)-formulated H5N1 pandemic
influenza DNA vaccine induced T-cell responses ...
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
... influenza vaccine
and with protein-based H5N1 pandemic
influenza vaccine currently stockpiled
by the ... the greatest number of people in the event of a pandemic
Data from additional ... for specific applications.
Influenza Vaccine Phase 1 Trial Update
ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
... to be effective, which is not
an option in a pandemic
situation," said Mansour. "Our depot vaccine
formulation makes a single-dose pandemic
flu vaccine a strong possibility."
IVT's strategy is multi-targeted; the company is exploring pandemic
seasonal influenza, as well as Hepatitis B. ...
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
... Potential to Address Gaps in Global pandemic
ROCKVILLE, Md., Aug. 26 ... of
the Phase I/IIa human clinical trial of its pandemic
particle (VLP) vaccine ... has the
potential to address an unmet need in pandemic
efforts being planned by ...
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
... achieve significant
immune responses against H5N1 pandemic
influenza in humans. DNA vaccines
are ... may offer compelling advantages
in response to a pandemic
outbreak because of significantly ... of the company's Vaxfectin(R)-formulated
influenza DNA vaccines demonstrated for the first ...
Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU
... with its intranasal vaccine deltaFLU
influenza. This novel generation of a ... The randomized, double-blind phase I study of the pandemic
deltaFLU will be run at the Department of ... in healthy volunteers.
Preclinical Data, pandemic
"Our vaccine lacks the pathogenicity ...
Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
... in its Phase II clinical trial for its
influenza vaccine. The preliminary results from ... Phase II clinical trial of Panflu(TM), its pandemic
(H5N1) whole viron inactivated vaccine. ... (H5N1).
Sinovac is currently developing Universal pandemic
Influenza vaccine and
Japanese encephalitis ...
Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
... poorest regions
of the world and an outbreak of pandemic
influenza would most likely hit
populations ... the forefront of readiness against
the threat of pandemic
influenza. The company is committed to ... program and in an ambitious seasonal and pandemic
vaccine production plan.
Each year ...
The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
... with the aim of protecting people against an H5N1 pandemic
infection," said Hartmut J. Ehrlich, MD. ... Agency,
making it the first cell culture-based pandemic
influenza vaccine to be
reviewed by the ... Ministry of Health to
supply 16 million doses of pandemic
influenza vaccine in the event a
pandemic is ...
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
... including a vaccine patch for pandemic
influenza in Phase II. - Intercell will ... an
immunostimulant vaccine patch in Phase II for pandemic
patch is designed to enhance the ... diarrhea available in the United States.
Three influenza pandemics have ...
Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
... vaccine. As the majority of current approaches
influenza vaccines require two doses, given 3 or ... in development: three targeting influenza and pandemic
one to prevent travelers' diarrhea. For ... health officials in addressing an
outbreak of pandemic
influenza; that the clinical trial data from the ...
Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
... in combination
with an injected vaccine for pandemic
influenza, and data from a prior
European trial ... of a
dose-sparing patch for use with a pandemic
influenza vaccine, and that
contract is currently funding the Phase 1/2 pandemic
influenza trial. The
patch being used in that ...
Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
... 1, 2007, Novavax has:
-- Advanced its H5N1 pandemic
influenza vaccine to Phase I/IIa clinical ... of 2008. The initial results from our pandemic
influenza study bode well for our seasonal ... 2007 with GE Healthcare to co-market a pandemic
influenza vaccine solution to select ...
Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
human clinical trial of its non-adjuvanted pandemic
particle (VLP) vaccine ... and support further development of our pandemic
through regulatory licensure. ... the vaccine as part of our contribution
flu preparedness planning. Novavax has the ...
GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
... a vaccine facility could allow manufacturing of
flu vaccine to commence within 12 weeks of the ... a
collaboration agreement to develop and market a pandemic
manufacturing solution for ... global avian flu
pandemic: the global demand for pandemic
influenza vaccine has been
reported as possibly ...
U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSC's DVC and Baxter
... patients in a Phase 1 clinical trial for a pandemic
2 strain vaccine candidate in ... conducted in
"The progress made on the pandemic
and seasonal influenza programs in
such a short ... to those using the vaccines
and for government pandemic
Baxter International ...
Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
... an update on the clinical trials for its pandemic
vaccines. Sinovac received approval in ... vaccine and Phase I and
II trials of its pandemic
influenza (H5N1) split vaccine. In the pandemic
influenza whole viron vaccine Phase II trial, a ...
Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
... particle ("VLP")-based vaccine candidates against pandemic
seasonal influenza. "Financial results for ... the Phase I/IIa clinical trial of our novel pandemic
vaccine from which scheduled top line results ... -- Scheduled results from our Phase I/IIa H5N1 pandemic
flu vaccine trial. Third Quarter Financial ...
Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region
... The exercise uses a hypothetical but realistic pandemic
flu outbreak in
Greater Washington as the ... has been paid in
recent years to preventing a pandemic
flu outbreak, and we're encouraged by
that," said ... set of events starting with the discovery of a pandemic
outbreak in South America. As the exercise ...
Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
... as a
dose-sparing agent with a protein-based H5N1 pandemic
currently stockpiled by the ... the greatest
number of people in the event of a pandemic
influenza outbreak. Alain
Rolland, Pharm.D., ... influenza vaccines against seasonal or pandemic
strains; whether Vical or others will ...
Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
... If successful,
Iomai's approach may expand the pandemic
influenza vaccine supply in the
event of an ... to
solve the pressing problem of inadequate pandemic
vaccine stocks, and we
believe the results of ... placebo injection or one of three dosages of pandemic
Patients will receive a ...
Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
... clinical sites. "We have designed a promising pandemic
influenza vaccine and
demonstrated its ... begun testing in
humans. The currently stockpiled pandemic
influenza vaccines primarily
generate antibody ... influenza vaccine in animals. pandemic
Influenza Vaccine Background ...
GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start.
... effectively respond to the global threat of a flu pandemic
and we are
pleased to be working with the US ... to U.S.
production of 150 million doses of pandemic
vaccine within six months of a
pandemic onset. ... and manufacture
cell-culture based seasonal and pandemic
influenza vaccines. These cell
culture vaccine ...
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
... of 2007, including
acceleration of the company's pandemic
influenza vaccine program, the
company is ... and
investments of $82 million at June 30, 2007. pandemic
Influenza IND Allowed
-- Vical has received ... of the company's Vaxfectin(TM)-formulated pandemic
influenza DNA vaccine, and now expects to ...
Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
... a pandemic. Baxter will manufacture its pandemic
vaccine in a serum-free, vero
cell-based system, ... to quickly respond to
emerging variant pandemic
virus strains. "We are proud to provide the ... further develop vero cell culture-based candidate pandemic
seasonal influenza vaccines in the United ...
Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
... strain change, which is expected to expedite the licensure process for the pandemic
"Filing this application is consistent with our ... evaluate the safety and potential benefits of adding an adjuvant to the pandemic
vaccine. More information on the influenza A(H1N1) 2009 vaccine clinical ...
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
... responses, both of which could be important in the face of a developing pandemic
where there are several variant virus forms circulating," said Jonathan ... to manufacture VRP vaccines and anticipate yields up to 1 million doses of pandemic
influenza vaccine per lot at the 1,000 L bioreactor scale. Since the ...
Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
... a broad-spectrum treatment countermeasure against bioterror and emerging pandemic
threats. The Hemopurifier(R) also holds promise in cancer care, as ... with drug therapy, including several of world's deadliest bioterror and pandemic
threats. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic ...
Insurance Industry Teleconference on Swine Flu Pandemic Set for May 13
... after the World Health Organization warned that a Swine Flu or A/H1N1 pandemic
is imminent, a prominent insurance law firm announced it will host a ... for the industry to do at this point is to learn as much as it can about pandemic
issues and responses to them by economies and by governments because the ...
Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
... today favorable preclinical results for a new broadly immunogenic pandemic
influenza virus-like particle (VLP) vaccine candidate that provided ... of inducing broad cross protection against a variety of strains with pandemic
potential without the use of an adjuvant. "It is extremely important to ...
NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
... and can
be produced rapidly to supply vaccine against an emerging pandemic
The company has also commenced a Phase II trial in healthy adults ... under development; current results may not be
predictive of future pandemic
results, results of our seasonal influenza
vaccine or any other vaccine ...